Shahid Beheshti University of Medical Sciences 2-4 Feb 2023



**Presentation Code:** G-02859



# Evaluation of novel treatments for advanced and relapsed / refractory Hodgkin lymphoma

## Sara Hosseinpour<sup>1</sup>, Mohammad Khani-Eshratabadi<sup>1,2</sup>

- 1. Department of Medical Laboratory Sciences, Kashmar School of Nursing, Mashhad University of Medical sciences, Mashhad, Iran
- 2. Department of Hematology and Blood Transfusion Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.

Shahid Beheshti University of Medical Sciences 2-4 Feb 2023



 Introduction 85% of patients Cured: Initial Therapy **Hodgkin lymphoma** Advanced and Relapsed / Refractory: Targeted Therapies 15% of patients **Understanding The** Mechanisms Of Oncogenicity Single-Agent **Identifying Various Vactors Of Combination Strategies Tumor Recurrence** 

Shahid Beheshti University of Medical Sciences 2-4 Feb 2023



Material & Method

**Narrative Review Article** 

2015 to 2023

262 Article







20 Article

Keywords

Hodgkin Lymphoma; Novel Treatment; Relapse; refractory, Brentuximab vedotin

Shahid Beheshti University of Medical Sciences 2-4 Feb 2023



Results

newly diagnosed classical HL

advanced-stage

Doxorubicin, Vinblastine, Dacarbazine

**Relapsed** HL

**After ASCT** 

Checkpoint Inhibitors ( Nivolumab and Pembrolizumab )


BV


consolidation after ASCT

Shahid Beheshti University of Medical Sciences 2-4 Feb 2023



# Conclusion





**Reference:** Gordon MR, Canakci M, Li L, Zhuang J, Osborne B, Thayumanavan S. Field guide to challenges and opportunities in antibody—drug conjugates for chemists. Bioconjugate chemistry. 2015 Nov 18;26(11):2198-215. Ahmed MM. CAR-T cell therapy: current advances and future research possibilities. Journal of Scientific Research in Medical and Biological Sciences. 2021 May 26;2(2):86-116.